Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 431-438

  Lacruz Guzmán, Diana ^a   Torres Moreno, Daniel ^b   Pedrero, Francisco ^c   Romero Cara, Patricia ^d   García Tercero, Iván ^d   Trujillo Santos, Javier ^d   Conesa Zamora, Pablo ^b  

^a Santa Lucia University Hospital HGUSL   (Spain)

^b HGUSL   (Spain)

^c Day Hospital   (Spain)

^d HUGSL   (Spain)

Author keywords

Crohn's disease; Infliximab; Interleukin 1; Pharmacogenetics; Tumour necrosis factor; Ulcerative colitis

Indexed keywords

INFLIXIMAB; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; GENE FREQUENCY; GENOTYPE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; MALE; PHENOTYPE; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84877115032     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1389-0     Document Type: Article

References (28)

1. Shih DQ, Targan SR, McGovern D (2008) Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep 10(6):568-575
2. Tsianos EV, Katsanos KH, Tsianos VE (2012) Role of genetics in the diagnosis and prognosis of Crohn's disease. World J Gastroenterol 18(2):105-118
3. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94(1):174-181
4. Reenaers C, Louis E, Belaiche J (2010) Current directions of biologic therapies in inflammatory bowel disease. Ther Adv Gastroenterol 3(2):99-106
5. González S, Rodrigo L, Martínez-Borra J, López-Vázquez A, Fuentes D, Niño P, Cadahía V, Saro C, Dieguez MA, López-Larrea C (2003) TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease. Am J Gastroenterol 98(5):1101-1106
6. Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J (2002) A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 37(7):818-824
7. Mascheretti S, Hampe J, Kühbacher T, Herfarth H, Krawczak M, Fölsch UR, Schreiber S (2002) Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2(2):127-136
8. Tomita K, Chiba T, Sugai T, Habano W (2010) Association between tumor necrosis factor-alpha and Fc-gamma receptor polymorphisms with infliximab in Crohn's disease. Hepatogastroenterology 57(99-100):535-539
9. Matsukura H, Ikeda S, Yoshimura N, Takazoe M, Muramatsu M (2008) Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease. Aliment Pharmacol Ther 27(9):765-770
10. Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P (2004) Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 20(3):303-310
11. Louis EJ, Watier HE, Schreiber S, Hampe J, Taillard F, Olson A, Thorne N, Zhang H, Colombel JF (2006) Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 16(12):911-914
12. Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55(6):749-753
13. Lichtiger S, Present DH, Kornbluth A et al (1994) Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330:1841-1845
14. Mata M, Morcillo E, Gimeno C, Cortijo J (2011) N-acetyl-l-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol 82(5):548-555
15. Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P (2012) Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine. doi: 10.1016/j.jbspin.2012.02.003
16. Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, Lantz PE, Isaacson PG (2008) Inflammatory bowel diseases. In: Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, Lantz PE, Isaacson PG (eds) Gastrointestinal pathology: an atlas and text. Lippincott Williams & Wilkins, Philadelphia, pp 593-689
17. Zabaleta J, Camargo MC, Piazuelo MB, Fontham E, Schneider BG, Sicinschi LA, Ferrante W, Balart L, Correa P, Ochoa AC (2006) Association of interleukin-1beta gene polymorphisms with precancerous gastric lesions in African Americans and Caucasians. Am J Gastroenterol 101(1):163-171
18. Cimaz R, Cazalis MA, Reynaud C, Gerloni V, Zulian F, Biggioggero M, Martini G, Pontikaki I, Fantini F, Mougin B, Miossec P (2007) IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Ann Rheum Dis 66(7):900-904
19. Carter KW, Hung J, Powell BL, Wiltshire S, Foo BT, Leow YC, McQuillan BM, Jennens M, McCaskie PA, Thompson PL, Beilby JP, Palmer LJ (2008) Association of Interleukin-1 gene polymorphisms with central obesity and metabolic syndrome in a coronary heart disease population. Hum Genet 124(3):199-206
20. Solovieva S, Kämäräinen OP, Hirvonen A, Hämäläinen S, Laitala M, Vehmas T, Luoma K, Näkki A, Riihimäki H, Ala-Kokko L, Männikkö M, Leino-Arjas P (2009) Association between interleukin 1 gene cluster polymorphisms and bilateral distal interphalangeal osteoarthritis. J Rheumatol 36(9):1977-1986
21. Yilmaz IA, Ozge A, Erdal ME, Edgünlü TG, Cakmak SE, Yalin OO (2010) Cytokine polymorphism in patients with migraine: some suggestive clues of migraine and inflammation. Pain Med 11(4):492-497
22. Na KS, Mok JW, Kim JY, Joo CK (2011) Proinflammatory gene polymorphisms are potentially associated with Korean non-Sjogren dry eye patients. Mol Vis 17:2818-2823
23. Camp NJ, Cox A, di Giovine FS, McCabe D, Rich W, Duff GW (2005) Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. Genes Immun 6(6):467-471
24. Tolusso B, Pietrapertosa D, Morelli A, De Santis M, Gremese E, Farina G, Carniello SG, Del Frate M, Ferraccioli G (2006) IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 7(5):683-695
25. Eklund C, Jahan F, Pessi T, Lehtimäki T, Hurme M (2003) Interleukin 1B gene polymorphism is associated with baseline C-reactive protein levels in healthy individuals. Eur Cytokine Netw 14(3):168-171
26. Martínez-Borra J, López-Larrea C, González S, Fuentes D, Dieguez A, Deschamps EM, Pérez-Pariente JM, López-Vázquez A, de Francisco R, Rodrigo L (2002) High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 97(9):2350-2356
27. Ozeki T, Furuya Y, Nagano C, Matsui C, Takayanagi R, Yokoyama H, Yamada Y (2006) Analysis of linkage between lymphotoxin alpha haplotype and polymorphisms in 5′-flanking region of tumor necrosis factor alpha gene associated with efficacy of infliximab for Crohn's disease patients. Mutat Res 602(1-2):170-174
28. Han Z, Li C, Han S, Han Y, Qiu J, Shi Y, Wang J, Sun A, Ding J, Wu K, Fan D (2010) Meta-analysis: polymorphisms in TNF-alpha gene promoter and Crohn's disease. Aliment Pharmacol Ther 32(2):159-170